Assessing albumin, ALC and PNI might improve prognostication in patients with myelofibrosis and could assist in recognition of patients under increased risk of death.
A mutation in the JAK2 gene is commonly found in patients with MPN, which can
sometimes lead to secondary AML. In this case study, we are reporting on an
interesting case of secondary AML originating from MDS-RARS-T. The patient had
no gross chromosomal changes, and we found that he was JAK2 V617F-mutated. His
BM showed 53% of myeloid blasts. After the induction of combined therapy of
Venetoclax and Azacytidine, a complete remission of the disease was achieved.
However, instead of the expected decrease in the mutated JAK2 alleles, we
documented a rise from the initial 55% to 79% of mutated alleles. This can be
explained by the fact that treatment for AML targets only one subclone.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.